Physician

Scott E Rojas, M.D.

According to 2025 Medicare claims, Scott Rojas, M.D. (NPI: 1285609784) practices infectious disease in the Savannah, GA market, with the plurality of this provider's patient population coming from Chatham, GA. This provider's primary affiliated billing organization is PRIVIA MEDICAL GROUP OF GEORGIA LLC (NPI: 1013313857; TIN: 202265068) and primary practice location at 31406-3928. Rojas is affiliated with the Privia Quality Network of Georgia (ACO ID: A3236) and TC2, LLC (ACO ID: A3365), participating under the MSSP model.

Rojas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 782 traditional Medicare patients, billed 76,822 HCPCS/CPT codes, and received $1,358,280 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,056 prescription claims across 183 beneficiaries totaling $2,002,146 in drug costs, led by Biktarvy (Bictegrav/Emtricit/Tenofov Ala). 2020 DME data shows 12 claims. Open Payments data shows 93 records totaling $12,682. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $388,792 to $1,358,280. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $420,081 to $2,002,146. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	727	30,249	$388,792
2016	668	61,003	$466,007
2017	581	7,780	$254,979
2018	603	7,197	$240,284
2019	597	34,778	$359,886
2020	679	72,499	$650,112
2021	710	54,863	$933,657
2022	683	61,880	$1,148,285
2023	786	81,313	$1,419,046
2024	782	76,822	$1,358,280

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	159	885	$420,081
2016	179	845	$667,855
2017	131	486	$501,982
2018	144	772	$1,115,560
2019	150	866	$1,240,071
2020	164	970	$1,648,571
2021	192	1,077	$1,340,141
2022	170	1,015	$1,681,818
2023	180	1,008	$1,859,003
2024	183	1,056	$2,002,146

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	63	$4,857
2016	N/R	95	$7,364
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	12	$166
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	252	275	$127
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	124	565	$85
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	252	1,171	$57
J0897	Injection, denosumab, 1 mg	267	25,800	$20
96372	Injection of drug or substance under skin or into muscle	279	384	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	286	8,580	$1,202,861
Juluca	Dolutegravir/Rilpivirine	31	930	$111,303
Cabenuva	Cabotegravir/Rilpivirine	12	660	$91,692
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	17	510	$76,978
Dovato	Dolutegravir Sodium/Lamivudine	23	690	$73,832

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	93	$12,682	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Scott E. Rojas, M.D.?

Tedicare shows public-source Medicare data for Scott E. Rojas, M.D. (NPI 1285609784), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Scott E. Rojas, M.D. have ACO affiliation data?

Scott E. Rojas, M.D. is shown with ACO affiliation data for Privia Quality Network of Georgia (MSSP, ACO ID A3236) and TC2, LLC (MSSP, ACO ID A3365).

What billing organization is linked to Scott E. Rojas, M.D.?

Scott E. Rojas, M.D. is linked to PRIVIA MEDICAL GROUP OF GEORGIA LLC (billing NPI 1013313857) in the available physician profile data.

Does Scott E. Rojas, M.D. have Open Payments data?

Scott E. Rojas, M.D. has 93 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.